2022 American Transplant Congress
Thymoglobulin Induction Protocol: Quality Improvement Project via Clinical Audit
*Purpose: The aim of our study was to analyze the adequacy of the thymoglobulin (rATG) induction protocol for the expanding and higher complexity kidney transplant…2021 American Transplant Congress
Association Between Cumulative Antithymocyte Globulin Dosing and Adverse Outcomes in Pediatric Heart Transplant Recipients
*Purpose: Lymphocyte depletion via rabbit antithymocyte globulin (rATG) is the most frequently used induction immunosuppressive in pediatric orthotopic heart transplant (OHT). Although outcomes are often…2021 American Transplant Congress
Continuous 24-Hour Antithymocyte Globulin (ATG) for Renal Allograft Rejection: Results of a Randomized Controlled Trial
Houston Methodist Hospital, Houston, TX
*Purpose: For acute renal allograft rejection (AR), ATG is generally administered in the inpatient setting because of the need for intravenous access, patient monitoring, and…2021 American Transplant Congress
Dosing Weight of Rabbit Antithymocyte Globulin and Outcomes Among Kidney Transplant Patients Treated for Rejection
Pharmacy, Northwestern Memorial Hospital, Chicago, IL
*Purpose: Rabbit antithymocyte globulin (rATG) is FDA approved for kidney transplant induction therapy and treatment of T-cell mediated rejection (TCMR). While prior studies comparing dosing…2021 American Transplant Congress
A Question with Multiple Answers: Do Renal Transplant Recipients Require Steroid Maintenance Following Thymoglobulin Induction?
Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: Anti-thymocyte globulin (ATG) has been used with good results in renal transplantation as induction therapy, followed by triple immunosuppression with calcineurin inhibitors, antimetabolites, and…2021 American Transplant Congress
Outcomes in Standard vs. Extended Use of Thymoglobulin as Induction Therapy in Kidney Transplant Recipients
*Purpose: Thymoglobulin induction along with modern maintenance immunosuppression has been found to have a significant reduction in acute rejection in kidney transplantation. The recommended duration…2021 American Transplant Congress
No Benefit of Antithymocyte Globulin in Living Donor Liver Transplant Recipients
Baylor University Medical Center, Dallas, TX
*Purpose: Acute rejection after liver transplant is associated with increased risk of graft failure and mortality. Reports on rejection rates in living donor liver transplants…2020 American Transplant Congress
Outcomes of Induction with T Lymphocyte-Depleting and IL-2 Receptor Blocking (IL-2RB) Antibodies in the Non-Broadly Sensitized Adult Deceased-Donor Kidney Transplant Recipients: Analysis in the Context of the CPRA Allocation System
*Purpose: We studied outcomes of induction in non-broadly-sensitized adult deceased-donor kidney transplant recipients(DD-KTRs) in the context of the calculated panel reactive antibody (CPRA) allocation system.*Methods:…2020 American Transplant Congress
Induction Therapy with Basiliximab versus Thymoglobulin in African-American Kidney Transplant Recipients in the Current Era of Immunosuppression
*Purpose: It is now common practice in the transplant community to select induction therapy on the basis of perceived immunological risk for acute rejection which…2020 American Transplant Congress
Renal Transplant Induction Therapy Safety Outcomes Comparison
*Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 8
- Next Page »